Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 395

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy of MEK inhibition in patients with histiocytic neoplasms

Open access
Diamond, Eli L., Durham, Benjamin H., Ulaner, Gary A., Drill, Esther, Buthorn, Justin, Ki, Michelle, Bitner, Lillian, Cho, Hana, Young, Robert J., Francis, Jasmine H., Rampal, Raajit, Lacouture, Mario, Brody, Lynn A., Ozkaya, Neval, Dogan, Ahmet, Rosen, Neal, Iasonos, Alexia, Abdel-Wahab, Omar, Hyman, David M.·2019·Nature

Abstract

Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway1,2. For the 50% of patients with histiocytosis who have BRAFV600 mutations3–5, RAF inhibition is highly efficacious and has markedly altered the natural history of the disease6,7. However, no standard therapy exists for the remaining 50% of patients who lack BRAFV600 mutations. Although ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of the kinase mutations that are found in patients who lack BRAFV600 mutations have not previously been biologically characterized. Here we show ERK dependency in histiocytoses through a proof-of-concept clinical trial of cobimetinib, an oral inhibitor of MEK1 and MEK2, in patients with histiocytoses. Patients were enrolled regardless of their tumour genotype. In parallel, MAPK alterations that were identified in treated patients were characterized for their ability to activate ERK. In the 18 patients that we treated, the overall response rate was 89% (90% confidence interval of 73–100). Responses were durable, with no acquired resistance to date. At one year, 100% of responses were ongoing and 94% of patients remained progression-free. Cobimetinib treatment was efficacious regardless of genotype, and responses were observed in patients with ARAF, BRAF, RAF1, NRAS, KRAS, MEK1 (also known as MAP2K1) and MEK2 (also known as MAP2K2) mutations. Consistent with the observed responses, the characterization of the mutations that we identified in these patients confirmed that the MAPK-pathway mutations were activating. Collectively, these data demonstrate that histiocytic neoplasms are characterized by a notable dependence on MAPK signalling—and that they are consequently responsive to MEK inhibition. These results extend the benefits of molecularly targeted therapy to the entire spectrum of patients with histiocytosis. A proof-of-concept clinical trial of patients with histiocytoses with MAPK-pathway mutations showed durable responses to treatment with the MEK1 and MEK2 inhibitor cobimetinib, which indicates that histiocytic neoplasms are dependent on MAPK signalling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1012-y

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 395

Metadata

Authors
Diamond, E. L., Durham, B. H., Ulaner, G. A., Drill, E., Buthorn, J., Ki, M., Bitner, L., Cho, H., Young, R. J., Francis, J. H., Rampal, R., Lacouture, M., Brody, L. A., Ozkaya, N., Dogan, A., Rosen, N., Iasonos, A., Abdel-Wahab, O., & Hyman, D. M.
Venue
Nature
Published
2019-03-13
Volume
567
Issue
7749
Pages
521-524
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2921153272
Cited by
395
References
32
FWCI
24.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of MEK inhibition in patients with histiocytic neoplasms. https://app.cochat.ai/papers/10.1038/s41586-019-1012-y
The paper
Diamond, E. L., Durham, B. H., Ulaner, G. A., Drill, E., Buthorn, J., Ki, M., Bitner, L., Cho, H., Young, R. J., Francis, J. H., Rampal, R., Lacouture, M., Brody, L. A., Ozkaya, N., Dogan, A., Rosen, N., Iasonos, A., Abdel-Wahab, O., & Hyman, D. M. (2019). Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. https://doi.org/10.1038/s41586-019-1012-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.